Core Insights - The training course on "EU Clinical Trial Regulation 536/2014" aims to provide comprehensive knowledge on compliance, implementation, and best practices for conducting clinical studies in the EU [1][2][4] Regulatory Framework - The course covers the requirements for conducting clinical studies under the EU Clinical Trial Regulation, including updates on EU-GCP and the new EU Pharmacovigilance Directive [2][3] - It discusses various licensing methods for Drugs, Biologics, and Combination Products, detailing the regulatory agencies' structure at the EU level and across Member States [3][4] Learning Objectives - Attendees will gain insights into the interaction between the EU and individual countries, registration procedures, and the impact of regulations on product development strategies [4][6] - The course aims to equip participants with strategies for streamlining the registration application process and understanding the concerns of European regulatory personnel [6][8] Key Topics - The training includes sessions on the new EU Regulation 536/2014, risk management in drug development, and the clinical trials application process [7][9] - Specific topics also cover investigational medicinal products (IMPs) and required documentation for compliance [9] Target Audience - The course is designed for a diverse audience, including quality assurance professionals, regulatory affairs experts, clinical operations staff, and investigators [8][10] - It aims to provide practical knowledge for effective trial conduct, submission processes, and compliance considerations [8][11]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Thermo Fisher Scientific will acquire clinical trial data firm Clario Holdings for $8.9 billion in cash, the companies announced Wednesday. Clario is currently held by a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven. In addition, Thermo has agreed to pay $125 million in January 2027, and up to $400 million in payments base ...

Core Insights - Three stocks are highlighted with strong buy rankings and positive momentum characteristics for investors to consider on October 28th Company Summaries Medpace (MEDP) - Medpace is a global, full-service clinical contract research organization providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries - The company has a Zacks Rank of 1 (Strong Buy) and the Zacks Consensus Estimate for its current year earnings has increased by 3.6% over the last 60 days - Medpace's shares have gained 31.7% over the last three months, significantly outperforming the S&P 500's gain of 7.6%, and it possesses a Momentum Score of A [1][2] Vertiv (VRT) - Vertiv is a leading global provider of critical digital infrastructure and services for data centers, communication networks, and commercial and industrial environments - The company also holds a Zacks Rank of 1 and has seen the Zacks Consensus Estimate for its current year earnings increase by 7.6% over the last 60 days - Vertiv's shares have increased by 35.4% over the last three months, again outperforming the S&P 500's gain of 7.6%, and it has a Momentum Score of A [2][3] TakeTwo Interactive Software (TTWO) - TakeTwo Interactive Software is a leading developer and publisher of video games - The company has a Zacks Rank of 1, with the Zacks Consensus Estimate for its current year earnings rising by 0.7% over the last 60 days - TakeTwo's shares have gained 12.4% over the last three months, surpassing the S&P 500's gain of 7.6%, and it has a Momentum Score of B [3][4]

Key Points Medpace's revenue growth was strong last quarter. The company is building up a backlog as the clinical trial sector recovers. Shares of Medpace are up 100% since the beginning of this year. 10 stocks we like better than Medpace › Shares of Medpace (NASDAQ: MEDP) zoomed 13% higher this week as of 11:49 a.m. ET on Friday, according to data from S&P Global Market Intelligence. The clinical research organization that helps pharmaceutical companies perform outsourced research and trial test ...

Market Overview - U.S. equity markets are experiencing a nuanced trading session influenced by corporate news and earnings reports, with mixed signals in major market indexes [1][2] - Premarket activity shows Nasdaq 100 and Dow Jones Industrial Average futures slightly lower, while S&P 500 futures indicate a marginal uptick, suggesting cautious optimism [2][3] Corporate Earnings - Tesla (TSLA) is set to announce Q3 2025 financial results, with analysts forecasting earnings per share of $0.48 on revenue of approximately $24.98 billion, while some predict Non-GAAP earnings per share of $0.66 and revenue of $28.4 billion [4] - Other companies reporting Q3 results include IBM, SAP, Boston Scientific Corp. (BSX), Medpace Holdings Inc. (MEDP), Molina Healthcare Inc. (MOH), and Thermo Fisher Scientific Inc. (TMO), providing insights into various sectors [5] Economic Indicators - The Bureau of Labor Statistics (BLS) will release "State Job Openings and Labor Turnover for August 2025," offering valuable labor market data [6] - An EIA report is also expected, providing insights into energy markets, while speeches from ECB officials may hint at global monetary policy direction [6] Major Corporate Developments - Tesla announced a recall of approximately 12,963 vehicles due to a potential battery pack contactor failure, which may impact stock performance despite mixed earnings prospects [7] - Microsoft (MSFT) reported CEO Satya Nadella's pay surged to $96.5 million, a 22% increase, attributed to advancements in AI and strong stock performance [11] - Alphabet (GOOGL) shares dipped 2% due to competition from OpenAI's new browser but rebounded 3.1% on news of a potential multi-billion dollar cloud deal with AI startup Anthropic [11] - Apple (AAPL) is reportedly cutting production orders for the new iPhone Air model due to weaker demand, leading to a 0.7% decline in shares [11] - Nvidia (NVDA) continues to be a key player in the AI sector, with a 31% gain in 2025, although some valuation models suggest it may be overvalued [11] - Hyatt Hotels Corporation (H) announced a franchise agreement to introduce 50 Hyatt Studios hotels in China, indicating expansion in the extended-stay segment [11] - Canon Inc. achieved a production milestone of over 170 million units in its RF/EF interchangeable lens series [11]

Market Overview - U.S. equities showed upward momentum in Q3, with the S&P 500 Index increasing by 8.1% and the Russell 3000 Index rising by 8.2% due to improved tariff outcomes, the passing of the One Big Beautiful Bill Act, anticipated interest rate cuts, and strong corporate earnings [2] - Growth stocks outperformed, with the Russell 3000 Growth Index up by 10.4%, surpassing its value counterpart by nearly 500 basis points [3] Sector Performance - The ClearBridge Select Strategy outperformed its benchmark for the second consecutive quarter, driven by contributions from consumer staples, communication services, IT, and industrials sectors [4] - Performance Food Group (PFGC) was a key contributor in consumer staples, boosted by activist investor interest and market share gains [5] - Reddit's advertising revenue surged by 84% year-over-year, leading to a higher valuation in communication services [6] - AppLovin's shares doubled due to strong earnings and optimism around its e-commerce business, expected to launch in Q4 [7] - L3Harris Technologies benefited from increased defense spending, while Comfort Systems saw steady demand from AI data center projects [8] Challenges and Detractors - Consumer discretionary and financials sectors faced headwinds, with MercadoLibre's stock declining due to competitive pressures and profit-taking [9] - Shift4 Payments experienced a negative reaction to disappointing Q2 results but raised its full-year guidance [10] - Concerns over generative AI impacting application software companies like ServiceNow and Fortinet led to losses, despite strong quarterly results [11] Portfolio Positioning - The company initiated eight new positions, including Regeneron Pharmaceuticals and Vertex Pharmaceuticals, while exiting five others [12][13] - Vistra, a major power generator, is well-positioned to benefit from tightening market conditions and potential federal subsidies [14] - Participation in the IPOs of Firefly Aerospace and Figma reflects confidence in growth prospects [15] Outlook - The market's rally is supported by improving trade sentiment, with expectations for gradual normalization of interest rates and clarity on tariffs [19] - The Russell 2000 Index showed significant outperformance, indicating a broadening of market leadership [20] - The macro backdrop is expected to remain volatile, but the portfolio is positioned for various market scenarios [24] Portfolio Highlights - The ClearBridge Select Strategy outperformed the Russell 3000 Index, with contributions from eight of the eleven sectors [25] - Stock selection in consumer staples and communication services, along with an overweight in IT, drove positive results [26] - Key contributors included AppLovin, Reddit, and L3Harris Technologies, while MercadoLibre and ServiceNow were notable detractors [27]

Core Insights - The U.S. market is experiencing significant turbulence due to renewed U.S.-China trade tensions, an ongoing government shutdown, and the start of the third-quarter earnings season [1][11] - Investors are closely monitoring key reports on inflation and jobs, as well as remarks from Fed Chair Powell that may influence rate expectations [2] - Amidst these uncertainties, value investing is gaining traction, focusing on fundamentally strong companies that are undervalued [2][11] Value Investing and Earnings Yield - Earnings yield is a crucial metric for identifying attractive value opportunities, calculated as annual earnings per share (EPS) divided by the market price [4] - Stocks with higher earnings yield are considered undervalued compared to those with lower earnings yield, which are seen as overpriced [5] - A stock's yield should be compared to the 10-year Treasury yield to assess its relative value; a higher yield indicates a potentially better investment for value investors [6] Screening Criteria for Stock Selection - The primary screening criterion is an earnings yield greater than 10%, supplemented by additional parameters such as estimated EPS growth and average daily trading volume [7][8] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) are expected to outperform peers in various market conditions [9] Top Stock Picks - **Allied Gold Corporation (AAUC)**: Expected EPS growth of 907% and 193% for 2025 and 2026, respectively, with a Zacks Rank 1 [12] - **Micron Technology Inc. (MU)**: Anticipated EPS growth of 100% and 12% for fiscal 2026 and 2027, respectively, also holding a Zacks Rank 1 [13] - **Fortrea Holdings Inc. (FTRE)**: Projected EPS growth of 63.6% and 64.5% for 2025 and 2026, with a Zacks Rank 1 [14] - **StoneCo Ltd. (STNE)**: Expected EPS growth of 20% and 17% for 2025 and 2026, respectively, and a Zacks Rank 1 [15] - **HF Sinclair Corporation (DINO)**: Forecasted EPS growth of 257.4% and 26.4% for 2025 and 2026, with a Zacks Rank 1 [16]

MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the successful completion of its third FDA inspection, further affirming the quality and compliance of its Direct-to-Patient Site for clinical research. The inspection concluded with a No Action Indicated (NAI) categorization recommendation by the inspector, with no objectionable conditions noted and no Form 483 issued. The review centered on Science 37’s contribution in ...

Photo by BeInCrypto Helius Medical Technologies is the latest medical company to pivot to a digital asset treasury, making it the fourth firm to take a similar step in recent months. These firms increasingly consider crypto investments a viable alternative to generate the growth their main drug development efforts have struggled to provide. Helius Trades Neurotech for Solana Helius Medical Technologies officially rebranded as Solana Company this week, becoming the latest medical corporation to pivot its ...

Core Viewpoint - FOXO Technologies Inc. has successfully completed the acquisition of Vector Biosource Inc., a provider of information, data, and biospecimen sourcing for the biotechnology and pharmaceutical research sectors, with expectations for significant growth post-acquisition [1][2]. Acquisition Details - The total purchase price for Vector includes: - $500,000 in cash - 60,000 shares of Series E Preferred Stock valued at $1.5 million - Warrants to purchase $2 million of common stock at a 10% premium - Up to an additional 80,000 shares of Series E Preferred Stock, contingent on achieving specific revenue and cash collection milestones within 12 to 24 months - FOXO will also fund up to $1.2 million for Vector's growth initiatives [2]. Financial Performance - Vector generated net revenues of approximately $225,000 in Q2 2025, translating to an annual run rate of about $0.9 million, indicating potential for significant growth following the acquisition [1][2]. Company Background - FOXO operates three main subsidiaries: - Rennova Community Health, which runs a critical access hospital in East Tennessee - Myrtle Recovery Centers, a behavioral health facility providing various treatment services - FOXO Labs, focused on biotechnology and health improvement through innovative technology [4][5]. Management Statements - FOXO's CEO expressed enthusiasm about the acquisition and the potential for growth through collaboration with Vector's management [2]. - Vector's CEO highlighted the partnership with FOXO as a means to achieve aggressive growth plans [2].